Moderna and GSK settle vaccine patent battle with zero royalties Facing demands for cuts of its COVID and RSV vaccine sales, Moderna walked away from a massive patent fight with GSK without paying a single dollar. A clean cross-license clears legal threats over its core shots, even as rival Pfizer remains on trial.
Moderna swings to profit and raises 2026 sales forecast Wall Street braced for another quarterly loss, but Moderna just reported $162 million in net profit. Multi-year government supply deals overseas drove $1.31 billion in sales, prompting management to lift 2026 revenue growth targets to 15% to 25%.
Pfizer Q3 Earnings Call Highlights Pfizer NYSE: PFE reported third-quarter 2026 revenue of $16.6 billion and raised its full-year outlook, citing growth in non-COVID products, contributions from launched and acquired medicines, and continued cost-control efforts.
Pfizer Inc. (PFE) Q3 2026 Earnings Call Transcript Pfizer Inc. ( PFE ) Q3 2026 Earnings Call November 3, 2026 10:00 AM EST Company Participants Francesca DeMartino - Chief Investor Relations Officer Albert Bourla - Chairman of the Board & CEO Cecile Guegan - Interim CFO & Executive VP Chris Boshoff - Chief Scientific Officer and President of Research & Development Alexandre de Germay - Executive VP & Chief International Commercial Officer Aamir Malik - Executive VP & Chief U.S. Commercial Officer Conference Call Participants Christopher Schott - JPMorgan Chase & Co, Research Division David Risinger - Leerink Partners LLC, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Akash Tewari - Jefferies LLC, Research Division Vamil Divan - Guggenheim Securities, LLC, Research Division Evan Seigerman - BMO Capital Markets Equity Research Steve Scala - TD Cowen, Research Division Geoffrey Meacham - Citigroup Inc., Research Division Alexandria Hammond - Wolfe Research, LLC Michael Yee - UBS Investment Bank, Research Division Asad Haider - Goldman Sachs Group, Inc., Research Division Presentation Operator Good day, everyone, and welcome to Pfizer's Third Quarter 2026 Earnings Conference Call. Today's call is being recorded.
Pfizer CEO Albert Bourla on Q3 earnings, patent expirations, obesity drug market CNBC's Annika Kim Constantino and Albert Bourla, Pfizer CEO, join 'The Exchange' to discuss Pfizer's Q3 earnings, patent expirations, and more.
Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial Three of the biggest names in pharma and vaccines are trading against their own headlines. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is at $231.
Roth IRA vs. Taxable Account: How Much of $11,400 in Dividends Would You Keep? Six high-yield stocks, one portfolio, and two very different tax bills waiting at the end of each year. Where you hold these positions matters far more than most investors realize before they file.
Nasdaq Surges 1%; Pfizer Posts Upbeat Q3 Earnings U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 1% on Tuesday.
UPS's $5.4 Billion Dividend Bill Exceeded Its Free Cash Flow. Is the Payout at Risk? Four stocks are paying out billions in dividends that their cash flows can barely support, and the gap between what investors expect and what the business can actually deliver keeps widening.
Q3 Earnings & JOLTS Report on Midterm Voting Day Early voting has seen some 60+ million Americans take to the ballot this year -- far ahead of normal levels of midterm voting.